Abstracts
Résumé
Les remaniements de la paroi bronchique, connus sous le nom de « remodelage des voies aériennes », touchent une partie des sujets asthmatiques. Ces altérations sont responsables d’un déclin progressif et irréversible de la fonction respiratoire et de la constitution d’un trouble ventilatoire obstructif irréversible et résistant aux thérapies conventionnelles, notamment aux corticoïdes. Le remodelage des voies aériennes se caractérise, entre autres, par des lésions épithéliales et une hyperplasie/hypertrophie/métaplasie des fibroblastes et des cellules musculaires lisses bronchiques. L’étude des mécanismes cellulaires et moléculaires qui gouvernent ces altérations tissulaires est l’étape indispensable à l’identification de nouvelles stratégies thérapeutiques préventives et/ou curatives.
Summary
Although asthma is classically defined as reversible airflow obstruction and often remits in younger subjects with milder disease, a proportion of asthmatics experience chronic symptoms, episodic exacerbations and persistent airway obstruction, despite the continuous use of β2-agonists, associated with high doses of inhaled/oral corticosteroids. These patients contribute to the majority of asthma costs through hospitalization, emergency visits, absence from work or school and use of medication. Although the mechanisms behind irreversible airflow obstruction in asthma are unclear, a prominent role has been attributed to persistent structural changes of the bronchial wall, defined as airway remodeling. Studies conducted on endobronchial biopsy samples have led to the histopathological characterization of these tissue alterations, which include chronic mucosal inflammation, extensive epithelial damage, collagen deposition, subepithelial fibrosis, increased mucous glands and airway smooth muscle hypertrophy and/or hyperplasia. Several factors, such as polypeptide growth factors and their receptors, matrix metalloproteases, intracellular molecules controlling cell death and survival, adhesion molecules and their ligands, as well a large variety of cytotoxic pro-inflammatory mediators are likely to contribute to the onset and maintenance of these tissue abnormalities. However, to date, the cellular and molecular events driving specifically these phenomena and allowing asthmatics with persistent airflow limitation to be distinguished from patients who normalize their bronchial obstruction upon adequate therapeutic management have not been identified yet. Accordingly, airway remodeling represents a major research challenge, particularly in view of the development of new therapeutic strategies specifically addressed at alleviating persistent bronchial obstruction in these otherwise intractable patients.
Appendices
Références
- 1. Gergen PJ. Understanding the economic burden of asthma. J Allergy Clin Immunol 2001; 107: S445-8.
- 2. Neukirch F, Pin I, Knani J, et al. Prevalence of asthma and asthma-like symptoms in three French cities. Respir Med 1995; 89: 685-92.
- 3. Guidelines for the Diagnosis and Management of Asthma. Expert Panareport 2. Atlanta, Ga: National Institute of Health, May 1997. National Heart, Lung and Blood Institute Publication n° 97-4051A.
- 4. Djukanovic R, Roche WR, Wilson JW, Beasley CRW, Twentyman OP, Howarth PH. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142: 434-57.
- 5. Barnes PJ. Mechanisms of action of glucocorticoids in asthma. Am J Respir Crit Care Med 1996; 154: 21-7.
- 6. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339: 1194-200.
- 7. Chung KF, Godard P. ERS task force: difficult therapy-resistant asthma. Eur Respir J 1999; 13: 1198-208.
- 8. Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. J Clin Invest 1999; 104: 1001-6.
- 9. Bousquet J, Jeffery P, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720-45.
- 10. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-80.
- 11. Jeffery PK. Remodeling in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: S28-38.
- 12. Vignola AM, Chiappara G, Gagliardo R, et al. Apoptosis and airway inflammation in asthma. Apoptosis 2000; 5: 473-85.
- 13. Druilhe A, Létuvé S, Pretolani M. Eosinophil apoptosis in asthma. Pathol Biol 2000; 48: 566-73.
- 14. Pretolani M. Remodeling of the respiratory tract in asthma. Biological factors and potential physiopathological implications in the apoptosis process. Rev Mal Respir 1999; 16: S27-8.
- 15. Anderson JM. Molecular structure of tight junctions and their role in epithelial transport. News Physiol Sci 2001; 16: 126-30.
- 16. Nievers MG, Schaapveld RQ, Sonnenberg A. Biology and function of hemidesmosomes. Matrix Biol 1999; 18:5-17.
- 17. Holgate ST, Davies DE, Lackie PM, Wilson SJ, Puddicombe SM, Lordan JL. Epithelial-mesenchymal interactions in the pathogenesis of asthma. Eur Respir J 2000; 105: 193-204.
- 18. Davies DE, Polosa R, Puddicombe SM, Richter A, Holgate ST. The epidermal growth factor receptor and its ligand family: their potential role in repair and remodelling in asthma. Allergy 1999; 54: 771-83.
- 19. Thompson AB, Robbins RA, Romberger DJ, et al. Immunological functions of the pulmonary epithelium. Eur Respir J 1995; 8: 127-49
- 20. Waters CM, Savla U. Keratinocyte growth factor accelerates wound closure in airway epithelium during cyclic mechanical strain. J Cell Physiol 1999; 181: 424-32.
- 21. Takeoka M, Ward WF, Pollack H, Kamp DW, Panos RJ. KGF facilitates repair of radiation-induced DNA damage in alveolar epithelial cells. Am J Physiol 1997; 272: L1174-80.
- 22. Okada-Ban M, Thiery JP, Jouanneau J. Fibroblast growth factor-2. Int J Biochem Cell Biol 2000; 32: 263-7.
- 23. Carpenter G, Wahl MI. The epidermal growth factor family. In: Sporn MB, Roberts AB, eds. Peptide growth factors and their receptors. New York: Springer-Verlag, 1991 : 69-171.
- 24. Puddicombe SM, Polosa R, Richter A, et al. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J 2000; 14: 1362-74.
- 25. Warburton D, Schwarz M, Tefft D, Flores-Delgado G, Anderson KD, Cardoso WV. The molecular basis of lung morphogenesis. Mech Dev 2000; 92: 55-81.
- 26. Johnson P, Maiti A, Brown KL, Li R. A role for the cell adhesion molecule CD44 and sulfation in leukocyte-endothelial cell adhesion during an inflammatory response? Biochem Pharmacol 2000; 59: 455-65.
- 27. Ilyas M, Tomlison IP. The interactions of APC, E-cadherin and β-catenin in tumour development and progression. J Pathol 1997; 182: 128-37.
- 28. Kikuchi A. Regulation of β-catenin signaling in the Wnt pathway. Biochem Biophys Res Commun 2000; 268: 243-8.
- 29. Stockinger A, Eger A, Wolf J, Beug H, Foisner R. E-cadherin regulates cell growth by modulating proliferation-dependent β-catenin transcriptional activity. J Cell Biol 2001; 154: 1185-96.
- 30. Goto Y, Uchida Y, Nomura A, et al. Dislocation of E-cadherin in the airways epithelium during an antigen-induced asthmatic response. Am J Respir Cell Mol Biol 2000; 23: 712-8.
- 31. Carayol N, Campbell A, Vachier I, et al. Modulation of cadherin and catenin expression by tumor necrosis factor-α and dexamethasone in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2002; 26: 341-7.
- 32. Hirst SJ, Walker TR, Chilvers ER. Phenotypic diversity and molecular mechanisms of airway smooth proliferation in asthma. Eur Respir J 2000; 16: 159-77.
- 33. Aikawa M, Palanisamy NS, Kuro-o M, et al. Human smooth muscle myosin heavy chain isoforms as molecular markers for vascular development and atherosclerosis. Circ Res 1993; 73: 1000-12.
- 34. Liu X, Shao Q, Dhalla NS. Myosin light chain phosphorylation in cardiac hypertrophy and failure due to myocardial infarction. J Mol Cell Cardiol 1995; 27: 2613-21.
- 35. McKay S, de Jongste JC, Saxena PR, Sharma HS. Angiotensin II induces hypertrophy of human airway smooth muscle cells: expression of transcription factors and transforming growth factor-β1. Am J Respir Cell Mol Biol 1998; 18: 823-33.
- 36. Panettieri RA, Murray RK, Eszterhs AJ, Bilgen G, Martin JG. Repeated allergen inhalations induce DNA synthesis in airway smooth muscle and epithelial cells in vivo. Am J Physiol Lung Cell Mol Physiol 1998; 274: L417-24.
- 37. Corrigan CJ, Brown PH, Barnes NC, et al. Glucocorticoid resistance in chronic asthma glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral-blood T-cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 1991; 144: 1016-25.
- 38. Adcock IM, Lane SJ, Brown CR, Peters MJ, Lee TH, Barnes PJ. Differences in binding of glucocorticoid receptor to DNA in steroid-resistant asthma. J Immunol 1995; 154: 3500-5.
- 39. Spector SL. Treatment of the unusually difficult asthmatic patients. Allergy Asthma Proc 1997; 18: 153-5.
- 40. Barnes PJ. Anti-IgE antibody therapy for asthma. N Engl J Med 1999; 341: 2006-8.
- 41. Barnes PJ. Endothelins and pulmonary diseases. J Appl Physiol 1994; 77: 1051-9.
- 42. Panettieri RA, Goldie RG, Rigby PJ, Eszterhas AJ, Hay DW. Endothelin-1-induced potentiation of human airway smooth muscle proliferation: an ETA receptor-mediated phenomenon. Br J Pharmacol 1996; 118: 191-7.
- 43. Burnouf C, Pruniaux MP. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharmaceutical Des 2002; 8: 1255-96.
- 44. Kohyama T, Liu XD, Zhu YK, et al. Phosphodiesterase inhibitor Cilomast inhibits fibroblasts-mediated collagen gel degradation induced by tumor necrosis factor-α. Am J Respir Cell Mol Biol 2002; 27: 487-94.